ACKNOWLEDGEMENTS
This study was supported by Bristol Myers Squibb and Ono Pharmaceutical Co. Ltd. We thank the patients and their families who made this study possible, the investigators and the clinical study teams at Bristol Myers Squibb (Princeton, NJ) and Ono Pharmaceutical Co. Ltd. (Osaka, Japan) and Dako (an Agilent Technologies Inc. company, Santa Clara, CA) for collaborative development of the PD‐L1 IHC 28‐8 pharmDx assay. Professional medical writing assistance was provided by Ben Labbe, PhD of Parexel, funded by Bristol Myers Squibb.